(Reuters) – Ironwood Pharmaceuticals Inc said on Tuesday its therapy to treat refractory gastroesophageal reflux disease failed to significantly reduce heartburn severity in a late-stage trial.
The company said it plans to reduce its workforce by nearly 35%, or 100 employees.
(Reporting by Dania Nadeem in Bengaluru; Editing by Shinjini Ganguli)
